Department of Radiology, Seoul National University Hospital, Seoul, Korea.
NMR Biomed. 2010 Jun;23(5):514-22. doi: 10.1002/nbm.1487.
This study was undertaken to compare the labeling efficiencies of three iron-oxide based MRI contrast agents [Feridex, Resovist and monocrystalline iron oxide (MION)] and to evaluate their effects on the biological properties of human mesenchymal stem cells (hMSCs). The hMSCs were cultivated for 1 and 7 days after 24-h labeling with iron oxide nanoparticles (12.5 microg Fe/mL) in the presence of poly-L-lysine (0.75 microg/mL). The hMSCs were labeled more efficiently with use of Feridex, Resovist as compared to MION. No significant differences were observed in terms of viability and proliferation of labeled hMSCs. The level of Oct-4 mRNA increased in labeled hMSCs at day 1 and the cellular phenotype changed from CD45-/CD44+/CD29+ to CD45low/CD44+/CD29+ at day 7, which closely resembles the phenotype of fresh bone marrow-derived hMSCs. Our study has demonstrated that the Feridex or Resovist is the preferred labeling agent for hMSCs. There was a change in Oct-4 and CD45 expression after labeling.
本研究旨在比较三种基于氧化铁的 MRI 对比剂（Feridex、Resovist 和单晶体氧化铁（MION））的标记效率，并评估它们对人骨髓间充质干细胞（hMSCs）生物学特性的影响。将 hMSCs 在多聚赖氨酸（0.75μg/mL）存在下用氧化铁纳米颗粒（12.5μg Fe/mL）标记 24 小时后，分别培养 1 天和 7 天。与 MION 相比，使用 Feridex 和 Resovist 可更有效地对 hMSCs 进行标记。标记 hMSCs 的活力和增殖无显著差异。在第 1 天，标记 hMSCs 中 Oct-4 mRNA 的水平增加，细胞表型从 CD45-/CD44+/CD29+变为 CD45low/CD44+/CD29+，这与新鲜骨髓来源的 hMSCs 的表型非常相似。我们的研究表明，Feridex 或 Resovist 是 hMSCs 的首选标记剂。标记后 Oct-4 和 CD45 的表达发生变化。
